Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IY001 and IY002 Drug-Drug Interaction Study
NCT07322991Phase 1Completed
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Oct 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of finasteride and tamsulosin in benign prostatic hyperplasia (BPH), sponsored by Il-Yang Pharmaceutical. Primary endpoints: Finasteride Area Under the Curve during the dosing interval at steady state at Day 8, Finasteride Maximum Plasma Concentration at steady state at Day 8 and 2 more. Started Oct 2025; status: completed.
02
Drugs
finasteridetamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT07322991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07322991.